

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

February 25, 2021

Duncan Peyton Chief Executive Officer 4D Pharma plc 5th Floor, 9 Bond Court Leeds LS1 2JZ United Kingdom

Re: 4D Pharma plc

Form F-4

Exhibit Nos. 10.1 and 10.2 Filed November 25, 2020 File No. 333-250986

Dear Mr. Peyton:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance